Cannabis and Blood Thinners: Critical Safety Information for Warfarin and Beyond

Medical Disclaimer: This article is strictly educational. It is not medical advice, and nothing here should replace a conversation with your prescribing physician or pharmacist. If you take any anticoagulant medication and use cannabis in any form — including CBD products — please discuss this with your healthcare provider before making any changes to your consumption or medication. Drug interactions with anticoagulants can be life-threatening. When in doubt, ask your doctor.

The Interaction Nobody Talks About

Here’s a number that might stop you mid-session: a well-documented case report describes a patient whose INR spiked from a stable 2.5 to 11.6 after beginning cannabis use [Yamreudeewong et al., 2009]. For context, a normal non-medicated INR sits around 1.0. Most warfarin patients are targeted at 2.0–3.0. At 11.6, you are in the territory of potentially life-threatening spontaneous bleeding.

Blood thinners (anticoagulants) are among the most widely prescribed medications in the world. They prevent the dangerous clots behind strokes, pulmonary embolisms, and heart attacks. They also operate on one of the narrowest therapeutic windows in all of medicine — meaning the margin between “working” and “causing you to bleed out” is thin in a way that other medications simply are not.

Now add cannabis to that equation. Cannabis contains dozens of bioactive compounds, and the two most abundant — THC and CBD — directly interact with the same liver enzyme system responsible for clearing these medications from your body. The result can be a dramatic and dangerous amplification of anticoagulant effects.

Yet most cannabis education resources gloss over this topic entirely. Many healthcare providers, still uncomfortable discussing cannabis use, don’t bring it up either. That leaves patients navigating a potentially life-altering pharmacological interaction in complete darkness.

This article changes that. We’re going to break down exactly how cannabis interacts with blood thinners at the molecular level, walk through the documented human case reports, assess what we know (and don’t know) about newer anticoagulants, explore THC vs. CBD differences, and give you concrete guidance on managing this risk. This isn’t fear-mongering — it’s harm reduction, delivered with the respect that serious pharmacology deserves.

Understanding Blood Thinners: The Basics

How Anticoagulants Work

To understand the interaction, you need to understand what these drugs actually do. Think of your blood’s clotting system as a cascade of dominoes: when you get a cut, a chain reaction of proteins called clotting factors activates in sequence until a clot forms and plugs the breach. It’s elegant, life-saving biology.

Anticoagulants work by interrupting that cascade at specific points.

Warfarin (sold as Coumadin or Jantoven) is the classic anticoagulant — in use since the 1950s and still one of the most prescribed drugs in the U.S. It blocks your liver’s ability to recycle vitamin K, which is an essential cofactor for producing several key clotting factors. Fewer functional clotting factors means slower clot formation and a lower risk of dangerous thromboembolism.

Direct Oral Anticoagulants (DOACs) are the newer generation and have largely displaced warfarin for many indications due to their more predictable pharmacokinetics:

• Rivaroxaban (Xarelto) — directly inhibits Factor Xa
• Apixaban (Eliquis) — directly inhibits Factor Xa
• Dabigatran (Pradaxa) — directly inhibits thrombin (Factor IIa)
• Edoxaban (Savaysa) — directly inhibits Factor Xa

Antiplatelet drugs operate on a related but distinct pathway. Medications like aspirin and clopidogrel (Plavix) prevent platelets — the cellular first responders in clot formation — from clumping together. They’re commonly used after stents, heart attacks, or in patients with peripheral arterial disease.

The Therapeutic Window Problem

The concept of the therapeutic window is central to why anticoagulant interactions are so dangerous. Unlike most medications — where the difference between a therapeutic and sub-therapeutic dose is primarily a matter of efficacy — with anticoagulants, the difference between doses can be the difference between a stroke and a hemorrhage.

Warfarin therapy is monitored through the INR (International Normalized Ratio), a standardized measure of how long it takes your blood to clot relative to normal. A healthy non-anticoagulated person has an INR around 1.0. Most warfarin patients are maintained between 2.0 and 3.0 (or 2.5–3.5 for mechanical heart valves). An INR above 4.0 significantly increases bleeding risk. An INR above 8.0 is considered a medical emergency.

The narrow therapeutic window is why warfarin patients require regular blood testing, why certain foods (especially vitamin K-rich vegetables) affect their levels, and why any new medication — or supplement, or herb — introduced into their regimen demands attention.

DOACs don’t require routine INR monitoring (a major advantage), but that same feature means that interactions affecting their levels may go undetected until a clinical bleeding or clotting event occurs.

The CYP450 Mechanism: Where Cannabis Meets Your Medication

The Liver as a Chemical Processing Plant

Your liver is an extraordinarily sophisticated chemical processing facility. Nearly every substance you consume — medication, food, drink, and yes, cannabis — is eventually metabolized there. The enzyme family doing the heavy lifting is called cytochrome P450 (CYP450), and it handles the breakdown of roughly 80% of all pharmaceutical drugs in clinical use [Zanger & Schwab, 2013].

CYP450 isn’t one enzyme — it’s a superfamily with dozens of specific isoforms, each specializing in certain molecular structures. The isoforms most relevant to cannabis and anticoagulants are:

• CYP2C9 — metabolizes the S-enantiomer of warfarin (the pharmacologically active form), NSAIDs, and some antidiabetic drugs. Approximately 10% of people are poor CYP2C9 metabolizers due to genetic variants, making them inherently more sensitive.
• CYP3A4 — the most abundant hepatic CYP enzyme, responsible for metabolizing roughly 50% of all pharmaceuticals [Zanger & Schwab, 2013]. Rivaroxaban and apixaban are significantly processed here.
• CYP2C19 — handles clopidogrel activation (it’s a prodrug that requires CYP2C19 to become active), as well as PPIs and some antidepressants.
• CYP2D6 — metabolizes many cardiovascular drugs, opioids, and antidepressants.

How Cannabis Inhibits These Enzymes

Both THC and CBD are themselves substrates of CYP450 enzymes — meaning the liver uses these same pathways to metabolize cannabinoids. But they don’t just use these lanes; they actively compete with and inhibit them, blocking the processing of other drugs that share the same metabolic pathway.

Think of the CYP450 system like a busy highway with multiple lanes. Your anticoagulant medication is traveling down the CYP2C9 lane at a predictable speed. When you consume CBD, it’s like merging a very slow truck into that lane and parking it there — your anticoagulant can’t get through, it backs up in your bloodstream, and its blood-thinning effect intensifies far beyond what your doctor intended.

The specific inhibitory profiles are well-characterized:

• CBD is a potent inhibitor of CYP2C9, CYP2C19, and CYP3A4 [Jiang et al., 2013; Yamaori et al., 2012]. Critically, CBD shows particularly strong inhibition of CYP2C9 — the primary enzyme responsible for clearing the active S-warfarin enantiomer.
• THC inhibits CYP3A4 and, to a lesser extent, CYP2C9 [Yamaori et al., 2010]. Its inhibitory effect on CYP2C9 is generally weaker than CBD’s, but still clinically relevant.
• THC-COOH and other metabolites contribute to the inhibitory burden as well, extending the interaction window beyond acute intoxication.

The research also points to an additional mechanism: cannabis cannabinoids can inhibit P-glycoprotein (P-gp), a transporter protein that helps eliminate drugs from cells, including dabigatran [Zhu et al., 2006]. This provides a second pathway for anticoagulant interactions even with drugs that primarily avoid CYP450 metabolism.

For patients on warfarin, the consequence of CYP2C9 inhibition is straightforward and dangerous: S-warfarin accumulates in the blood, its anticoagulant effect amplifies, and INR rises — sometimes dramatically.

Why CBD May Be More Dangerous Than THC for This Interaction

This is counterintuitive to many people who assume CBD is “the safe one,” but the research tells a different story when it comes to drug interactions.

CBD is a more potent inhibitor of CYP2C9 than THC [Yamaori et al., 2012]. Since CYP2C9 is the primary clearance pathway for the active form of warfarin, CBD may produce greater INR elevations than equivalent amounts of THC.

This is particularly relevant given the explosion of CBD wellness products — oils, tinctures, capsules, and gummies — that people take daily, often at high doses (25–150+ mg/day), without understanding the drug interaction risk. Someone taking CBD for anxiety, sleep, or pain while also on warfarin could be creating a serious, silent hazard.

The good news about THC: while it does inhibit CYP enzymes, it does so less potently than CBD for the specific enzymes most critical to warfarin metabolism. However, this is not a reason to consider THC safe in this context — merely that the magnitude of interaction may differ.

What the Research Actually Shows: Case Reports and Evidence

The evidence base for cannabis-anticoagulant interactions is built primarily on case reports, pharmacokinetic modeling, and in vitro enzyme studies. Randomized controlled trials don’t exist for this interaction, largely because deliberately inducing potential bleeding emergencies in research subjects would be unethical. But the mechanistic evidence is sound, and the case reports are compelling.

Documented Warfarin-Cannabis Interactions

The Yamreudeewong Case (2009)

This is the most-cited case in the literature and the most dramatic. A 56-year-old man on stable warfarin therapy (with a therapeutic INR around 2.5) began smoking cannabis regularly. Over several weeks, his INR climbed to 11.6. He had no dietary changes, no new medications, and no illness to explain the elevation. After cannabis cessation, his INR returned to therapeutic range. The authors concluded this represented a probable pharmacokinetic drug interaction mediated by CYP450 inhibition [Yamreudeewong et al., 2009].

The Grayson/Szaflarski Case (2018)

A patient on stable warfarin for a mechanical mitral valve began taking pharmaceutical-grade CBD (Epidiolex) at escalating doses as part of a compassionate-use epilepsy treatment program. As the CBD dose increased, the patient’s INR rose non-linearly — meaning the INR didn’t just creep up proportionally; it climbed steeply as CBD reached higher concentrations. The patient required significant warfarin dose reductions to maintain a therapeutic INR. When CBD was discontinued, warfarin doses had to be increased again. This case elegantly demonstrated the dose-dependent nature of the interaction [Grayson et al., 2018].

The Broader Literature: Four Case Reports and Counting

A 2022 narrative review in PMC identified four case reports of clinically significant interactions between CBD-containing products and warfarin [Nasrin et al., 2022]. All four involved elevated INR values that required clinical intervention. The review noted that no published studies existed at that time examining CBD interactions with DOACs — a gap that reflects both the newness of DOAC use and the historical barriers to cannabis research.

A 2023 systematic review in Pharmacotherapy confirmed that anticoagulant-cannabinoid drug-drug interactions are clinically relevant, with warfarin representing the most well-documented risk. The review also noted emerging concern for DOAC interactions via shared metabolic pathways, even without published case reports [Greger et al., 2023].

The 2022 Oromucosal Case — A Counterpoint

Not all cases tell the same story. A 2022 case report in the Journal of Cannabis Research described an 85-year-old patient on chronic warfarin who began an oromucosal cannabis regimen containing 0.3 mg THC and 5.3 mg CBD daily and showed minimal INR fluctuations over approximately one year [Stout et al., 2022]. The authors noted the very low cannabinoid doses and oromucosal route as potentially explaining the lack of significant interaction.

This case is important because it illustrates that the interaction is dose- and route-dependent rather than absolute. Very low CBD doses through a route with low systemic absorption may not inhibit CYP enzymes significantly. But this cannot be extrapolated to higher doses, different routes, or different patients.

The Bottom Line on Evidence

The honest picture: we have mechanistically sound pharmacokinetic data, multiple case reports of clinically significant interactions with warfarin, and a systematic review confirming the concern — all without large randomized controlled trials. The absence of RCTs doesn’t mean the interaction is uncertain; it means the evidence is of the type available when running controlled trials is ethically constrained.

Every major drug interaction database — including Drugs.com, Clinical Pharmacology, and Lexicomp — flags cannabis/CBD interactions with warfarin as clinically significant. These classifications aren’t made speculatively; they’re based on the accumulated mechanistic and case report evidence.

Direct Oral Anticoagulants (DOACs): The Evidence Gap

If you’re on Eliquis, Xarelto, or Pradaxa rather than warfarin, you might be tempted to assume you’re safer. That assumption deserves scrutiny.

Rivaroxaban (Xarelto)

Rivaroxaban is metabolized by CYP3A4/5, CYP2J2, and P-glycoprotein. The prescribing label for Xarelto explicitly warns that strong CYP3A4 inhibitors combined with P-gp inhibitors can significantly increase rivaroxaban exposure — raising both bleeding risk and plasma concentration.

Both CBD and THC inhibit CYP3A4. CBD also inhibits P-gp. In theory, this creates precisely the pharmacokinetic combination that rivaroxaban’s label warns against.

A case report from the J&J Xarelto medical information page describes a 16-year-old with superficial venous thrombosis and chronic cannabis use who experienced progression of clots despite rivaroxaban therapy, eventually requiring a switch to low-molecular-weight heparin. While this case involves a different direction of concern (possible thrombotic failure rather than bleeding), it illustrates that the cannabis-rivaroxaban relationship is clinically unpredictable.

No large published studies exist on this interaction. Absence of evidence is not evidence of absence — particularly for a drug combination that only became plausible as cannabis legalization expanded in the same era as DOAC adoption.

Apixaban (Eliquis)

Apixaban shares rivaroxaban’s CYP3A4 and P-gp metabolic pathways. The same theoretical concerns apply. At the time of the most recent systematic review (2022), no published case reports or studies existed specifically examining CBD or cannabis interactions with apixaban [Nasrin et al., 2022]. The interaction database entry on Drugs.com currently shows no listed interaction — but the authors caution that absence from databases reflects absence of published data, not established safety.

Dabigatran (Pradaxa)

Dabigatran is unusual among DOACs because it does not undergo significant CYP450 metabolism. It is primarily cleared via P-glycoprotein transport. This would theoretically reduce its CYP-mediated interaction risk with cannabinoids — except that CBD is also a P-gp inhibitor [Zhu et al., 2006]. A P-gp interaction with dabigatran could increase its plasma levels and bleeding risk through this alternative pathway.

The Honest Assessment

DOACs were designed partly to avoid warfarin’s notorious drug and food interactions. But they are not interaction-free, and the cannabinoid pathways that matter for DOACs (CYP3A4, P-gp) are the same ones that cannabinoids inhibit. Until we have robust clinical data — which requires the kind of cannabis research infrastructure that is only now beginning to develop — treating DOACs as definitively safe to combine with cannabis would be premature.

Antiplatelet Drugs: A Different Mechanism, Similar Concerns

While we’ve focused primarily on anticoagulants, antiplatelet drugs present a related set of concerns worth understanding.

Aspirin works by irreversibly inhibiting cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and blunting platelet aggregation. Cannabis itself — particularly via its effects on the endocannabinoid system — may have platelet-modifying properties.

Research published in PLOS ONE found that endocannabinoids (particularly anandamide) inhibit platelet activation and aggregate formation, with ex vivo data showing that humans who consumed cannabis had impaired collagen-induced platelet aggregation compared to controls [Murugalla et al., 2014]. This platelet-inhibitory effect, combined with aspirin’s pharmacological action, raises concerns about additive or synergistic bleeding risk — particularly in patients on aspirin/NSAID combinations or dual antiplatelet therapy.

Clopidogrel (Plavix) introduces another layer of complexity: it is a prodrug that requires conversion to its active form by CYP2C19. CBD is a known inhibitor of CYP2C19 [Nasrin et al., 2021]. In theory, CBD could reduce the conversion of clopidogrel to its active metabolite, reducing antiplatelet efficacy — potentially increasing clot risk rather than bleeding risk. This is the opposite direction of concern compared to warfarin, but equally dangerous for patients with stents or other high-thrombotic-risk conditions.

Practical Guidance: If You Use Cannabis and Blood Thinners

This is the section that matters most. Here’s how to translate everything above into actionable decisions:

1. Disclose Your Cannabis Use to Your Doctor — Completely and Specifically

This is non-negotiable. Your prescribing physician or pharmacist needs to know:

• What cannabinoids you use (CBD, THC, or both)
• In what form (smoked, vaped, edibles, oil, tincture, capsules)
• At what dose (as specifically as you know)
• How frequently (daily, weekly, occasionally)

Many patients fear judgment, and that fear is understandable given decades of stigma. But the medical landscape is changing rapidly, and your safety depends on honest communication. If your current provider isn’t receptive to an honest conversation about cannabis use, that’s a signal worth taking seriously about the quality of that therapeutic relationship.

2. Request More Frequent INR Monitoring if You’re on Warfarin

If you use cannabis while on warfarin — or are considering starting either — ask your doctor to schedule more frequent INR checks during any period of change. This includes:

• Starting or stopping cannabis use
• Changing your cannabis dose or product
• Switching between consumption methods
• Changing the cannabinoid ratio in your products (e.g., adding a high-CBD product)

The goal is to catch INR drift early, before it reaches dangerous levels.

3. Understand That CBD Products May Carry MORE Risk Than THC-Dominant Cannabis

This is the counterintuitive finding that matters most for public health. CBD wellness products are often perceived as safe, non-psychoactive supplements. But for warfarin patients specifically, the research suggests CBD may be a stronger inhibitor of the critical CYP2C9 pathway than THC.

If you’re taking CBD oil, CBD capsules, or high-CBD tinctures daily while on warfarin, this interaction concern is particularly acute. The high doses common in CBD wellness use (50–150 mg/day or more) can produce substantial CYP2C9 inhibition.

4. Oral Cannabis Products Are Likely Riskier Than Inhaled Forms

When you inhale cannabis (smoke or vapor), cannabinoids enter the bloodstream through the lungs, partially bypassing the liver on first pass. When you take oral products — edibles, tinctures swallowed rather than held sublingually, capsules, or CBD oils — everything routes through the liver via first-pass metabolism, maximizing direct hepatic enzyme inhibition.

This doesn’t make inhaled cannabis safe to combine with blood thinners. But it may mean that the same milligram dose causes more pronounced CYP450 inhibition when delivered orally. For patients on anticoagulants, this is one of many factors worth discussing with a pharmacist.

5. Consistency Matters if You Choose to Continue

One of the subtler risks in this interaction is irregular use. If you occasionally use cannabis but not consistently, your INR will fluctuate each time you start and stop — making it nearly impossible for your doctor to dial in a stable warfarin dose. If you and your healthcare provider determine that continued cannabis use is acceptable with appropriate monitoring, maintaining a consistent, stable pattern (same product, same dose, same frequency) allows for warfarin dose adjustments based on reliable baseline levels.

6. Know the Warning Signs of Over-Anticoagulation

Be vigilant for these symptoms, which can indicate your blood-thinning effect has climbed too high:

• Unusual bruising, especially large bruises from minor contact
• Nosebleeds that won’t stop after 10–15 minutes of pressure
• Blood in urine (pink, red, or cola-colored)
• Blood in stool or black, tarry stools
• Coughing up blood
• Unusually heavy or prolonged menstrual bleeding
• Bleeding gums during normal brushing
• Sudden severe headache, confusion, or vision changes (possible intracranial bleeding — seek emergency care immediately)

Do not hesitate to seek medical attention if you experience these symptoms while on any anticoagulant medication.

The Broader Drug Interaction Context

Understanding cannabis-blood thinner interactions becomes even more important when you place it within the broader landscape of cannabis-drug interactions. As we explored in detail in our piece on cannabis and medication interactions, the CYP450 inhibition caused by cannabinoids is not limited to blood thinners. The same mechanisms that amplify warfarin affect a broad spectrum of medications.

For patients managing complex cardiovascular conditions, the potential interactions extend across the full medication stack:

Medication Class	Examples	Interaction Mechanism	Direction of Concern
Vitamin K antagonists	Warfarin (Coumadin)	CYP2C9, CYP3A4 inhibition	INR increase, bleeding risk
Direct Xa inhibitors	Xarelto, Eliquis	CYP3A4, P-gp inhibition	Drug level increase, bleeding risk
Direct thrombin inhibitors	Pradaxa	P-gp inhibition	Drug level increase, bleeding risk
Antiplatelet agents	Plavix (clopidogrel)	CYP2C19 inhibition	Reduced activation, thrombotic risk
NSAIDs/aspirin	Ibuprofen, aspirin	Additive platelet inhibition	Additive bleeding risk
Beta-blockers	Metoprolol, carvedilol	CYP2D6 inhibition	Drug level increase
Statins	Atorvastatin, simvastatin	CYP3A4 inhibition	Drug level increase, myopathy risk

The general pharmacological principle bears repeating: if a medication is metabolized by CYP2C9, CYP3A4, CYP2C19, or P-glycoprotein, cannabinoids — especially CBD — may affect its blood levels. For medications with narrow therapeutic windows (anticoagulants being the clearest example), even modest increases in plasma concentration can have serious clinical consequences.

For a broader survey of how cannabis interacts across medication classes, including antidepressants, seizure medications, and immunosuppressants, our comprehensive drug interaction guide covers the full landscape.

Cardiovascular Context

Cannabis and cardiovascular health is a topic worthy of its own deep dive — which we’ve provided in our cardiovascular research breakdown. The short version relevant here: THC’s acute cardiovascular effects (transient heart rate increase, blood pressure changes) can add an additional layer of concern for patients who are already managing vascular conditions that require anticoagulation. Atrial fibrillation, mechanical heart valves, DVT, and pulmonary embolism are the most common reasons people are on blood thinners — all conditions where cardiovascular stability matters enormously.

The pharmacokinetic interaction (enzyme inhibition) and the pharmacodynamic effects (heart rate, blood pressure) are separate concerns that can compound each other in vulnerable populations.

Frequently Asked Questions

Can I use a CBD topical (cream, lotion) while on blood thinners?

Topical CBD products — when properly formulated and not applied to broken skin — have very limited systemic absorption. The concern about CYP450 inhibition is primarily a systemic (oral, inhaled, or sublingual) absorption issue. Occasional use of a CBD topical for localized muscle soreness is unlikely to produce the plasma CBD concentrations necessary for significant enzyme inhibition. However, large-area application, damaged skin barriers, or high-potency topicals could increase systemic absorption. When in doubt, mention it to your pharmacist.

Is there a “safe” level of cannabis use alongside blood thinners?

The evidence base doesn’t support defining a universally safe dose. The interaction is dose-dependent — meaning lower cannabis doses produce less enzyme inhibition — but the threshold at which inhibition becomes clinically meaningful varies based on your specific anticoagulant, your dose, your individual CYP450 enzyme activity (which varies by genetics), and other factors. Some patients may use cannabis at low doses with careful INR monitoring and limited impact. Others may show large INR changes at modest doses. The only way to know where you fall on that spectrum is close monitoring under medical supervision.

How long after stopping cannabis does the CYP interaction resolve?

Cannabis cannabinoids persist in adipose tissue and can be detected in blood and urine for days to weeks depending on frequency of use and individual metabolism. The enzyme inhibition effect begins to diminish as cannabinoid plasma levels fall. For a regular daily user stopping cannabis, the full washout period may take 1–2 weeks or longer. During this period, your anticoagulant levels may rise as CYP2C9 inhibition is lifted — paradoxically, stopping cannabis could initially increase your drug exposure. INR should be monitored closely during transitions.

I started cannabis before my blood thinner. Is my current INR accurate?

If you have been using cannabis consistently at the same dose and frequency for a period before starting your anticoagulant, your prescribing provider may have inadvertently dosed against an already-inhibited CYP baseline. If you then reduce or stop cannabis use, your warfarin may become more effective than expected (since the enzyme inhibition lifts). The safest approach is to disclose your cannabis use, let your provider document the baseline, and monitor INR through any changes.

Should I tell my pharmacist, not just my doctor?

Absolutely — and this is often underappreciated. Pharmacists are among the most accessible and well-trained medication interaction specialists in the healthcare system. They have access to interaction databases, understand CYP450 pharmacology, and can provide nuanced guidance about your specific drug combination. Many are increasingly informed about cannabinoid interactions. If you’re uncomfortable discussing cannabis use with your prescribing physician, starting with a pharmacist can be a lower-stakes entry point that still gets you important safety information.

Key Takeaways

The mechanism is real. CBD and THC inhibit CYP2C9 and CYP3A4 — the primary enzymes that clear warfarin and metabolize several DOACs. This is not theoretical; it is established pharmacokinetics.

Documented cases confirm clinical significance. Case reports document INR values climbing to 11.6 in a warfarin patient after cannabis use. A second case showed dose-dependent INR escalation with pharmaceutical CBD. Multiple published reviews have classified this as a clinically significant drug interaction.

CBD may be riskier than THC for warfarin patients. CBD inhibits CYP2C9 more potently than THC. High-dose CBD wellness products may pose a greater interaction risk than THC-dominant cannabis.

DOACs are not immune. Rivaroxaban and apixaban share CYP3A4 and P-gp metabolic pathways with cannabinoid inhibitory activity. The evidence gap reflects limited research, not established safety.

Oral cannabis products may produce more interaction than inhaled. First-pass hepatic metabolism maximizes cannabinoid-enzyme contact for edibles, tinctures, and capsules.

Consistency matters. Irregular cannabis use creates unpredictable INR fluctuations that are harder to manage clinically than steady-state use.

Disclosure is not optional. Your safety depends on honest, complete communication with your prescribing physician and pharmacist about all cannabis use, including CBD products.

Sources

• Yamreudeewong, W., Wong, H.K., Brausch, L.M., & Bode, K.R. (2009). Probable interaction between warfarin and marijuana smoking. Annals of Pharmacotherapy, 43(7), 1347–1353. PMID: 19638481

• Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., & Watanabe, K. (2012). Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol. Life Sciences, 88(15–16), 730–736. PMID: 21356216

• Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2010). Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metabolism and Disposition, 39(11), 2049–2056. PMID: 21821735

• Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2013). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences, 89(5–6), 165–170. PMID: 21756922

• Grayson, L., Vines, B., Nichol, K., & Szaflarski, J.P. (2018). An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports, 9, 10–11. PMID: 29462009

• Greger, J., Bates, V., Mechtler, L., & Gengo, F. (2019). A review of cannabis and interactions with anticoagulant and antiplatelet agents. Journal of Clinical Pharmacology, 60(4), 432–438. PMID: 31724188

• Nasrin, S., Watson, C.J.W., Perez-Paramo, Y.X., & Lazarus, P. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes. Drug Metabolism and Disposition, 49(3), 239–248. PMID: 33372050

• Nasrin, S., Watson, C.J.W., & Lazarus, P. (2022). Potential drug interactions between cannabinoids and oral anticoagulants. PMC (NCBI). PMC9065521

• Stout, S.M., et al. (2022). Case report: Medical cannabis—warfarin drug-drug interaction. Journal of Cannabis Research. PMID: 35000222. DOI: 10.1186/s42238-021-00112-x

• Zanger, U.M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103–141. PMID: 23333322

• Zhu, H.J., Wang, J.S., Markowitz, J.S., et al. (2006). Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. Journal of Pharmacology and Experimental Therapeutics, 317(2), 850–857. PMID: 16547090

• Mueck, W., Kubitza, D., & Becka, M. (2014). Co-administration of rivaroxaban with drugs that share its elimination pathways. British Journal of Clinical Pharmacology, 76(3), 455–466. PMID: 23802624

• Murugalla, L.R., et al. (2014). Endocannabinoids control platelet activation and limit aggregate formation under flow. PLOS ONE. DOI: 10.1371/journal.pone.0108282

• Lucas, C.J., Galettis, P., & Schneider, J. (2018). The pharmacokinetics and pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology, 84(11), 2477–2482. PMID: 30001569